<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054153</url>
  </required_header>
  <id_info>
    <org_study_id>20210802ZJS001</org_study_id>
    <nct_id>NCT05054153</nct_id>
  </id_info>
  <brief_title>Westlake Precision Nutrition Study</brief_title>
  <official_title>Westlake Precision Nutrition Study: Diet Challenges for Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westlake University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Westlake University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dietary intervention study, which aims to explore different diet challenges for&#xD;
      glucose metabolism, including carbohydrates and intermittent fasting (IF) dietary pattern.&#xD;
      Considering the glucose responses to the same food are largely heterogeneous among people,&#xD;
      this study integrates the concepts of precision nutrition and N-of-1 design. The study also&#xD;
      aims to explore differences in brain structure and function between participants with&#xD;
      different Body Mass Index (BMI) from the perspective of gut-brain axis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims for precision nutrition. Participants will be required to wear continuous&#xD;
      glucose monitoring (CGM) for 14 days. The diet intervention will be carried out after wearing&#xD;
      CGM on Day 1. Individual N-of-1 trial design will be employed during Day 2 to Day 7 to&#xD;
      compare the difference of postprandial glucose response to white bread or plain oats. These&#xD;
      two breakfasts will appear in alternating order every successive 2 days, and these successive&#xD;
      2 days will be defined as one set. There will be 3 sets during Day 2 to Day 7. Between lunch&#xD;
      and dinner will be the wash out period for the remaining effect of the last breakfast&#xD;
      intervention on blood glucose homeostasis. In this period, participants will be allowed to&#xD;
      choose foods without restrictions, but dietary records are required. The period during Day 8&#xD;
      to Day 14 is defined as intermittent fasting (IF) period, and participants will experience&#xD;
      moderate fasting on Day 9 and Day 13 with total energy intake restrained within 500-600 kcal.&#xD;
      In these two fasting days, participants will be provided with daily three meals.&#xD;
      Investigators will closely monitor participants' latent adverse response and compliance to&#xD;
      ensure the intervention will be completed with adequate safety and high compliancy. Oral&#xD;
      glucose tolerance test (OGTT) will be conducted in the morning of Day 8 and Day 14 to test&#xD;
      the changes of glucose tolerance before and after one set of IF intervention.&#xD;
      Electroencephalogram (EEG) and functional Magnetic Resonance Imaging (fMRI) scanning will be&#xD;
      conducted as per standard procedure at baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">February 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood glucose profiling</measure>
    <time_frame>14 days</time_frame>
    <description>Real-time blood glucose fluctuations will be recorded by CGM.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of glucose tolerance before and after intermittent fasting</measure>
    <time_frame>Day 8 and Day 13</time_frame>
    <description>Oral glucose tolerance test will also be conducted.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Changes of fecal and urine metabolomics profiling</measure>
    <time_frame>Day 1, Day 8 , Day 11 and Day 14</time_frame>
    <description>Fecal and urine metabolite extracts will be analyzed by performing liquid chromatography/quadrupole time-of-flight mass spectrometry (LC/Q-TOF/MS).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of serum metabolomics profiling</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Targeted metabolomics are analyzed based on serum.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of interleukin-1β (IL-1β), IL-6, IL-12</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Serum inflammatory factors (including IL-1β, IL-6, and IL-12) will be tested by enzyme-linked immunosorbent assay (ELISA) in pg/mL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of tumor necrosis factor-α (TNF-α)</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Serum level of TNF-α will be tested by ELISA in ng/mL.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of serum dopamine</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Dopamine will be analyzed by serum.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of serum 5-hydroxytryptamine</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>5- hydroxytryptamine will be analyzed by serum.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of serum gamma-aminobutyric acid</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Gamma-aminobutyric acid will be analyzed by serum.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of lipid metabolism</measure>
    <time_frame>Day 1, and Day 14</time_frame>
    <description>Triglyceride, cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, apolipoprotein A1 and apolipoprotein B.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of weight</measure>
    <time_frame>Day 1, Day 8 , Day 11 and Day 14</time_frame>
    <description>Weight will be measured in kilograms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>Day 1</time_frame>
    <description>Height will be measured in centimeters.</description>
  </other_outcome>
  <other_outcome>
    <measure>Body composition</measure>
    <time_frame>at enrollment</time_frame>
    <description>Body composition (fat mass, lean mass in kg ) are assessed by bioelectrical impedance analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes of both systolic and diastolic blood pressure</measure>
    <time_frame>Day 1, Day 8 , Day 11 and Day 14</time_frame>
    <description>Both systolic and diastolic blood pressure will be measured in mmHg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Electroencephalograph(EEG) N2 and P3 amplitudes</measure>
    <time_frame>at enrollment</time_frame>
    <description>Event-related potentials (N2 and P3 amplitudes) of brain will be assessed by EEG in μV.</description>
  </other_outcome>
  <other_outcome>
    <measure>Brain images</measure>
    <time_frame>at enrollment</time_frame>
    <description>Brain structure and function was measured by brain magnetic resonance imaging (MRI)</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Healthy</condition>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>refined carbohydrate breakfast (Breakfast A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>white bread (50g) + milk powder (25g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>whole grain breakfast (Breakfast B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>plain oats (35g) + milk powder (25g)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intermittent fasting (IF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>refined carbohydrate breakfast</intervention_name>
    <description>After wearing CGM on Day 1, participants will be provided with breakfast A once daily on Day 2, Day 5 and Day 6. Breakfast A contains white bread (50g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.</description>
    <arm_group_label>refined carbohydrate breakfast (Breakfast A)</arm_group_label>
    <other_name>Breakfast A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>whole grain breakfast</intervention_name>
    <description>After wearing CGM on Day 1, participants will be provided with Breakfast B once daily on Day 3, Day 4 and Day 7. Breakfast B contains plain oats (35g) and milk powder (25g). Since lunch and dinner would serve as wash-out meals, participants will be free to choose food but provide a record of their diets.</description>
    <arm_group_label>whole grain breakfast (Breakfast B)</arm_group_label>
    <other_name>Breakfast B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>intermittent fasting</intervention_name>
    <description>The period during Day 8 to Day 13 is intermittent fasting period. Participants will experience the moderate fasting on Day 9 and Day 12, which means their daily energy intake is expected to be controlled within 500-600 kcal limit. In these two days, participants will be provided with all three meals. Percentages of macronutrients of provided meals will follow the Recommended Dietary Health guidelines for Chinese residents. The oral glucose tolerance test (OGTT) will be conducted in the morning on Day 8 and Day 13, to test short-term impact of IF intervention on individuals' glucose tolerance. The breakfasts on Day 10 and Day 11 will be the same as that in fasting days. Other meals will be wash-out meals.</description>
    <arm_group_label>intermittent fasting (IF)</arm_group_label>
    <other_name>IF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants reside in Hangzhou&#xD;
&#xD;
          -  Participants have no traveling plans within 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusing or unable to give informed consent&#xD;
&#xD;
          -  Participants with chronic gastrointestinal diseases and take daily relevant&#xD;
             medications&#xD;
&#xD;
          -  Participants with metabolic diseases including diabetes, hypertension and&#xD;
             cardiovascular diseases (CVD)&#xD;
&#xD;
          -  Participants with craniocerebral trauma, cancer, liver disease, kidney disease, or&#xD;
             other critical illness, or history of operation or medication&#xD;
&#xD;
          -  Participants with bulimia nervosa, post-traumatic stress disorder (PTSD), chronic&#xD;
             anxiety and depression or other critical neuronal disorder or history of relevant&#xD;
             medication&#xD;
&#xD;
          -  Being or to be pregnant or lactating.&#xD;
&#xD;
          -  Participants with history of alcohol or drug addiction, or smoke above 15 cigarettes&#xD;
             per day&#xD;
&#xD;
          -  Concurrently participating other clinical trials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ju-Sheng Zheng, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Westlake University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ju-Sheng Zheng, PhD</last_name>
    <phone>86-0571-86915303</phone>
    <email>zhengjusheng@westlake.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ke Zhang, Bachelor</last_name>
    <phone>86-18888641943</phone>
    <email>zhangke@westlake.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Westlate University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310024</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju-Sheng Zheng, PhD</last_name>
      <phone>86-0571-86915303</phone>
      <email>zhengjusheng@westlake.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ke Zhang</last_name>
      <phone>86-0571-86915303</phone>
      <email>zhangke@westlake.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glucose Metabolism</keyword>
  <keyword>Intermittent fasting</keyword>
  <keyword>Personalized Nutrition</keyword>
  <keyword>Brain</keyword>
  <keyword>Gut Microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

